Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Targeted polypharmacology is a promising strategy for treating complex diseases like cancer.
• Discovering compounds with advantageous activity profiles is crucial for effective polypharmacology.
• Transforming growth factor-beta-activated kinase 1 (TAK1) is a key kinase in cancer signaling pathways.

Purpose of the Study:

• To discover and validate novel covalent inhibitors of TAK1.
• To assess the polypharmacology and cellular efficacy of these inhibitors.
• To evaluate their potential for developing multi-targeting TAK1-centered cancer therapies.

Main Methods:

• Synthesis and validation of novel covalent TAK1 inhibitors.
• Cellular assays to measure TAK1 kinase inhibition and polypharmacology.
• Comparison of inhibitor efficacy and selectivity profiles with known compounds.
• Use of a biotinylated derivative to confirm target engagement in cells.

Main Results:

• Several novel covalent TAK1 inhibitors were identified with potent efficacy.
• Compound 5 demonstrated significant potency in both RAS-mutated and wild-type RAS cancer cell lines.
• The inhibitors exhibited comparable efficacy and complementary kinase selectivity to 5Z-7-oxozaenol.
• Cellular TAK1 binding was confirmed using a biotinylated derivative.

Conclusions:

• The newly developed covalent TAK1 inhibitors are effective tools for cancer research.
• These compounds can be further developed into multi-targeting TAK1-centered therapies.
• Targeted polypharmacology using these inhibitors holds promise for treating various cancers.